Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Cerevel Therapeutics Holdings, Inc. Market Cap
Based on ratings from 9 stock analysts, the Cerevel Therapeutics Holdings, Inc. stock price is expected to increase by 3.65% in 12 months. This is calculated by using the average 12-month stock price forecast for Cerevel Therapeutics Holdings, Inc.. The lowest target is $25.00 and the highest is $45.00. Please note analyst price targets are not guaranteed and could be missed completely.
About 9 Wall Street analysts have assignedCERE 0 buy ratings, 9 hold ratings, and 0 sell ratings. This means that analysts expect Cerevel Therapeutics Holdings, Inc. to hold. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on CERE. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| jessica fye J.P. Morgan | Hold | $45.0 | maintained | Dec 28, 2023 |
| mohit bansal Wells Fargo | Hold | $45.0 | maintained | Dec 22, 2023 |
| michael yee Jefferies | Hold | $45.0 | downgraded | Dec 22, 2023 |
| paul matteis Stifel Nicolaus | Hold | $43.0 | downgraded | Dec 18, 2023 |
| douglas tsao H.C. Wainwright | Hold | $45.0 | downgraded | Dec 7, 2023 |
| graig suvannavejh Mizuho Securities | Hold | $25.0 | maintained | Dec 7, 2023 |
| joseph thome TD Cowen | Hold | $45.0 | downgraded | Dec 7, 2023 |
| david amsellem Piper Sandler | Hold | $45.0 | downgraded | Dec 7, 2023 |
| charles duncan Cantor Fitzgerald | Hold | $45.0 | rated | Dec 6, 2023 |
| matthew harrison Morgan Stanley | Buy | $38.0 | maintained | Nov 2, 2023 |
| tazeen ahmad Bank of America Securities | Hold | $31.0 | rated | Aug 3, 2023 |
| caroline palomeque Berenberg Bank | Hold | $24.0 | maintained | Aug 3, 2023 |
| madhu kumar Goldman Sachs | Hold | $30.0 | maintained | May 23, 2023 |
| umer raffat Evercore ISI | Buy | None | reiterated | Mar 20, 2023 |
| esther hong Loop Capital Markets | Buy | $38.0 | maintained | Feb 23, 2023 |
| cory kasimov J.P. Morgan | Buy | $49.0 | maintained | May 10, 2022 |
| andrew tsai Jefferies | Buy | $18.0 | initiatedcoverage | Nov 23, 2020 |
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures in epilepsy or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; and CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and PDE4 inhibitor for the treatment of psychiatric, neuroinflammatory, and other disorders. Cerevel Therapeutics Holdings, Inc. was founded in 2018 and is headquartered in Cambridge, Massachusetts.
When did it IPO
2020
Staff Count
321
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Mr. Ronald C. Renaud Jr., M.B.A.
Market Cap
$7.43B
In 2023, CERE generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that CERE's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2019
Revenue From 2020
Revenue From 2021
Revenue From 2022
CYTK-USD
$76.5
DUOL-USD
$174.26
$73.7
LYFT-USD
$17.91
RGLD-USD
$108.65
ACHC-USD
$84.63
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
